1	CONTROLLED SUBSTANCE AMENDMENTS	
2	2006 GENERAL SESSION	
3	STATE OF UTAH	
4	Chief Sponsor: Curtis Oda	
5	Senate Sponsor: Gregory S. Bell	
6	Cosponsors: Gregory H. Hughes Paul Ray	
7		
8	LONG TITLE	
9	General Description:	
10	This bill amends the Controlled Substances Act to clarify the scope of the exception	
11	established for the ceremonial use of peyote by Indians in traditional Indian religion and	
12	to provide an affirmative defense.	
13	Highlighted Provisions:	
14	This bill:	
15	<ul> <li>provides definitions in the Controlled Substances Act of "Indian," "Indian religion,"</li> </ul>	
16	and "Indian tribe" in order to provide for the determination of individuals who are	
17	members of Indian tribes regarding the peyote use exemption;	
18	<ul> <li>provides an affirmative defense against a charge for possession of peyote if used by</li> </ul>	
19	an Indian in an Indian religious ceremony, as these terms are defined in this bill; and	
20	<ul> <li>provides related qualifying language regarding driving with any measurable</li> </ul>	
21	controlled substance in the body.	
22	Monies Appropriated in this Bill:	
23	None	
24	Other Special Clauses:	
25	None	
26	<b>Utah Code Sections Affected:</b>	
27	AMENDS:	
28	41-6a-517, as renumbered and amended by Chapter 2 and last amended by Chapter	
29	283, Laws of Utah 2005	

30 58-37-2, as last amended by Chapter 283, Laws of Utah 2005 58-37-4, as last amended by Chapter 33, Laws of Utah 2003 31 32 **58-37-8**, as last amended by Chapter 30, Laws of Utah 2005 33 34 *Be it enacted by the Legislature of the state of Utah:* 35 Section 1. Section 41-6a-517 is amended to read: 41-6a-517. Definitions -- Driving with any measurable controlled substance in the 36 37 body -- Penalties -- Arrest without warrant. 38 (1) As used in this section: (a) "Controlled substance" means any substance scheduled under Section 58-37-4. 39 40 (b) "Practitioner" has the same meaning as provided in Section 58-37-2. 41 (c) "Prescribe" has the same meaning as provided in Section 58-37-2. (d) "Prescription" has the same meaning as provided in Section 58-37-2. 42 43 (2) In cases not amounting to a violation of Section 41-6a-502, a person may not 44 operate or be in actual physical control of a motor vehicle within this state if the person has any 45 measurable controlled substance or metabolite of a controlled substance in the person's body. 46 (3) It is an affirmative defense to prosecution under this section that the controlled 47 substance was: 48 (a) involuntarily ingested by the accused [or]; 49 (b) prescribed by a practitioner for use by the accused[-]; or 50 (c) otherwise legally ingested. (4) (a) A person convicted of a violation of Subsection (2) is guilty of a class B 51 52 misdemeanor. 53 (b) A person who violates this section is subject to conviction and sentencing under 54 both this section and any applicable offense under Section 58-37-8. 55 (5) A peace officer may, without a warrant, arrest a person for a violation of this 56 section when the officer has probable cause to believe the violation has occurred, although not 57 in the officer's presence, and if the officer has probable cause to believe that the violation was

**Enrolled Copy** 

H.B. 60

58	committed by the person.
59	(6) The Driver License Division shall:
60	(a) suspend, for 90 days, the driver license of a person convicted under Subsection (2);
61	(b) revoke, for one year, the driver license of a person convicted of a second or
62	subsequent offense under Subsection (2) or if the person has a prior conviction as defined
63	under Subsection 41-6a-501(2), if the violation is committed within a period of ten years after
64	the date of the prior violation; and
65	(c) subtract from any suspension or revocation period the number of days for which a
66	license was previously suspended under Section 53-3-223 or 53-3-231, if the previous
67	suspension was based on the same occurrence upon which the record of conviction is based.
68	(7) (a) The court shall notify the Driver License Division if a person fails to:
69	(i) complete all court ordered screening and assessment, educational series, and
70	substance abuse treatment; or
71	(ii) pay all fines and fees, including fees for restitution and treatment costs.
72	(b) Upon receiving the notification, the division shall suspend the person's driving
73	privilege in accordance with Subsections 53-3-221(2) and (3).
74	(8) The court shall order supervised probation in accordance with Section 41-6a-507
75	for a person convicted under Subsection (2).
76	Section 2. Section <b>58-37-2</b> is amended to read:
77	58-37-2. Definitions.
78	(1) As used in this chapter:
79	(a) "Administer" means the direct application of a controlled substance, whether by
80	injection, inhalation, ingestion, or any other means, to the body of a patient or research subject
81	by:
82	(i) a practitioner or, in his presence, by his authorized agent; or
83	(ii) the patient or research subject at the direction and in the presence of the

(b) "Agent" means an authorized person who acts on behalf of or at the direction of a

84

85

practitioner.

manufacturer, distributor, or practitioner but does not include a motor carrier, public warehouseman, or employee of any of them.

- (c) "Consumption" means ingesting or having any measurable amount of a controlled substance in a person's body, but this Subsection (1)(c) does not include the metabolite of a controlled substance.
- (d) "Continuing criminal enterprise" means any individual, sole proprietorship, partnership, corporation, business trust, association, or other legal entity, and any union or groups of individuals associated in fact although not a legal entity, and includes illicit as well as licit entities created or maintained for the purpose of engaging in conduct which constitutes the commission of episodes of activity made unlawful by Title 58, Chapters 37, 37a, 37b, 37c, or 37d, which episodes are not isolated, but have the same or similar purposes, results, participants, victims, methods of commission, or otherwise are interrelated by distinguishing characteristics. Taken together, the episodes shall demonstrate continuing unlawful conduct and be related either to each other or to the enterprise.
- (e) "Control" means to add, remove, or change the placement of a drug, substance, or immediate precursor under Section 58-37-3.
- (f) (i) "Controlled substance" means a drug or substance included in Schedules I, II, III, IV, or V of Section 58-37-4, and also includes a drug or substance included in Schedules I, II, III, IV, or V of the federal Controlled Substances Act, Title II, P.L. 91-513, or any controlled substance analog.
  - (ii) "Controlled substance" does not include:
- (A) distilled spirits, wine, or malt beverages, as those terms are defined or used in Title 32A, <u>Alcoholic Beverage Control Act</u>, regarding tobacco or food;
- (B) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counter medication without prescription; or
- (C) dietary supplements, vitamins, minerals, herbs, or other similar substances

including concentrates or extracts, which are not otherwise regulated by law, which may contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules adopted pursuant to Title 63, Chapter 46a, Utah Administrative Rulemaking Act.

- (g) (i) "Controlled substance analog" means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in Schedules I and II of Section 58-37-4, or in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513:
- (A) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances in the schedules set forth in Subsection (1)(f); or
- (B) which, with respect to a particular individual, is represented or intended to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances in the schedules set forth in this Subsection (1).
  - (ii) "Controlled substance analog" does not include:

- (A) a controlled substance currently scheduled in Schedules I through V of Section 58-37-4;
  - (B) a substance for which there is an approved new drug application;
  - (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 366, to the extent the conduct with respect to the substance is permitted by the exemption;
  - (D) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance;
  - (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counter medication without prescription; or
    - (F) dietary supplements, vitamins, minerals, herbs, or other similar substances

142 including concentrates or extracts, which are not otherwise regulated by law, which may 143 contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules 144 adopted pursuant to Title 63, Chapter 46a, Utah Administrative Rulemaking Act. 145 (h) "Conviction" means a determination of guilt by verdict, whether jury or bench, or plea, whether guilty or no contest, for any offense proscribed by Title 58, Chapters 37, 37a, 146 147 37b, 37c, or 37d, or for any offense under the laws of the United States and any other state 148 which, if committed in this state, would be an offense under Title 58, Chapters 37, 37a, 37b, 149 37c, or 37d. 150 (i) "Counterfeit substance" means: 151 (i) any substance or container or labeling of any substance that without authorization 152 bears the trademark, trade name, or other identifying mark, imprint, number, device, or any 153 likeness of them, of a manufacturer, distributor, or dispenser other than the person or persons 154 who in fact manufactured, distributed, or dispensed the substance which falsely purports to be a 155 controlled substance distributed by, any other manufacturer, distributor, or dispenser; or 156 (ii) any substance that is represented to be a controlled substance. 157 (j) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a 158 controlled substance or a listed chemical, whether or not an agency relationship exists. 159 (k) "Department" means the Department of Commerce. 160 (1) "Depressant or stimulant substance" means: 161 (i) a drug which contains any quantity of barbituric acid or any of the salts of barbituric acid; 162 163 (ii) a drug which contains any quantity of: 164 (A) amphetamine or any of its optical isomers; 165 (B) any salt of amphetamine or any salt of an optical isomer of amphetamine; or 166 (C) any substance which the Secretary of Health and Human Services or the Attorney General of the United States after investigation has found and by regulation designated 167 168 habit-forming because of its stimulant effect on the central nervous system;

(iii) lysergic acid diethylamide; or

(iv) any drug which contains any quantity of a substance which the Secretary of Health and Human Services or the Attorney General of the United States after investigation has found to have, and by regulation designated as having, a potential for abuse because of its depressant or stimulant effect on the central nervous system or its hallucinogenic effect.

- (m) "Dispense" means the delivery of a controlled substance by a pharmacist to an ultimate user pursuant to the lawful order or prescription of a practitioner, and includes distributing to, leaving with, giving away, or disposing of that substance as well as the packaging, labeling, or compounding necessary to prepare the substance for delivery.
  - (n) "Dispenser" means a pharmacist who dispenses a controlled substance.
- (o) "Distribute" means to deliver other than by administering or dispensing a controlled substance or a listed chemical.
  - (p) "Distributor" means a person who distributes controlled substances.
- (q) "Division" means the Division of Occupational and Professional Licensing createdin Section 58-1-103.
  - (r) "Drug" means:

- (i) articles recognized in the official United States Pharmacopoeia, Official Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any supplement to any of them;
- (ii) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals;
- (iii) articles, other than food, intended to affect the structure or function of man or other animals; and
- (iv) articles intended for use as a component of any articles specified in Subsection (1)(r)(i), (ii), or (iii); but does not include devices or their components, parts, or accessories.
- (s) "Drug dependent person" means any individual who unlawfully and habitually uses any controlled substance to endanger the public morals, health, safety, or welfare, or who is so dependent upon the use of controlled substances as to have lost the power of self-control with reference to his dependency.

198	(t)	"Food"	means
1/0	( ,	1 000	means

- (i) any nutrient or substance of plant, mineral, or animal origin other than a drug as specified in this chapter, and normally ingested by human beings; and
- (ii) foods for special dietary uses as exist by reason of a physical, physiological, pathological, or other condition including but not limited to the conditions of disease, convalescence, pregnancy, lactation, allergy, hypersensitivity to food, underweight, and overweight; uses for supplying a particular dietary need which exist by reason of age including but not limited to the ages of infancy and childbirth, and also uses for supplementing and for fortifying the ordinary or unusual diet with any vitamin, mineral, or other dietary property for use of a food. Any particular use of a food is a special dietary use regardless of the nutritional purposes.
- (u) "Immediate precursor" means a substance which the Attorney General of the United States has found to be, and by regulation designated as being, the principal compound used or produced primarily for use in the manufacture of a controlled substance, or which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit the manufacture of the controlled substance.
  - (v) "Indian" means a member of an Indian tribe.
- (w) "Indian religion" means any religion:
- 217 (i) the origin and interpretation of which is from within a traditional Indian culture or 218 community; and
  - (ii) which is practiced by Indians.
    - (x) "Indian tribe" means any tribe, band, nation, pueblo, or other organized group or community of Indians, including any Alaska Native village, which is legally recognized as eligible for and is consistent with the special programs, services, and entitlements provided by the United States to Indians because of their status as Indians.
    - [(v)] (y) "Manufacture" means the production, preparation, propagation, compounding, or processing of a controlled substance, either directly or indirectly by extraction from

substances of natural origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis.

- [(w)] (z) "Manufacturer" includes any person who packages, repackages, or labels any container of any controlled substance, except pharmacists who dispense or compound prescription orders for delivery to the ultimate consumer.
- [(x)] (aa) "Marijuana" means all species of the genus cannabis and all parts of the genus, whether growing or not; the seeds of it; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or resin. The term does not include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of the mature stalks, except the resin extracted from them, fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination. Any synthetic equivalents of the substances contained in the plant cannabis sativa or any other species of the genus cannabis which are chemically indistinguishable and pharmacologically active are also included.
- [(y)] (bb) "Money" means officially issued coin and currency of the United States or any foreign country.
- [(z)] (cc) "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
  - (i) opium, coca leaves, and opiates;
- (ii) a compound, manufacture, salt, derivative, or preparation of opium, coca leaves, or opiates;
  - (iii) opium poppy and poppy straw; or
- (iv) a substance, and any compound, manufacture, salt, derivative, or preparation of the substance, which is chemically identical with any of the substances referred to in Subsection (1)[(z)](cc)(i), (ii), or (iii), except narcotic drug does not include decocainized coca leaves or extracts of coca leaves which do not contain cocaine or ecgonine.

254 [<del>(aa)</del>] (dd) "Negotiable instrument" means documents, containing an unconditional 255 promise to pay a sum of money, which are legally transferable to another party by endorsement 256 or delivery. 257 [(bb)] (ee) "Opiate" means any drug or other substance having an addiction-forming or 258 addiction-sustaining liability similar to morphine or being capable of conversion into a drug 259 having addiction-forming or addiction-sustaining liability. [(cc)] (ff) "Opium poppy" means the plant of the species papayer somniferum L.. 260 261 except the seeds of the plant. 262 [(dd)] (gg) "Person" means any corporation, association, partnership, trust, other 263 institution or entity or one or more individuals. [(ee)] (hh) "Poppy straw" means all parts, except the seeds, of the opium poppy, after 264 265 mowing. 266 [ff] (ii) "Possession" or "use" means the joint or individual ownership, control, 267 occupancy, holding, retaining, belonging, maintaining, or the application, inhalation, 268 swallowing, injection, or consumption, as distinguished from distribution, of controlled 269 substances and includes individual, joint, or group possession or use of controlled substances. 270 For a person to be a possessor or user of a controlled substance, it is not required that he be 271 shown to have individually possessed, used, or controlled the substance, but it is sufficient if it 272 is shown that the person jointly participated with one or more persons in the use, possession, or 273 control of any substances with knowledge that the activity was occurring, or the controlled 274 substance is found in a place or under circumstances indicating that the person had the ability 275 and the intent to exercise dominion and control over it. 276 [(gg)] (ii) "Practitioner" means a physician, dentist, veterinarian, pharmacist, scientific 277 investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted to 278 distribute, dispense, conduct research with respect to, administer, or use in teaching or 279 chemical analysis a controlled substance in the course of professional practice or research in 280 this state.

[(hh)] (kk) "Prescribe" means to issue a prescription orally or in writing.

(A) Acetyl-alpha-methylfentanyl

	• •
282	[(ii)] (ll) "Prescription" means an order issued by a licensed practitioner, in the course
283	of that practitioner's professional practice, for a controlled substance, other drug, or device
284	which it dispenses or administers for use by a patient or an animal. The order may be issued by
285	word of mouth, written document, telephone, facsimile transmission, computer, or other
286	electronic means of communication as defined by rule.
287	[(jj)] (mm) "Production" means the manufacture, planting, cultivation, growing, or
288	harvesting of a controlled substance.
289	[(kk)] (nn) "Securities" means any stocks, bonds, notes, or other evidences of debt or of
290	property.
291	[(H)] (oo) "State" means the state of Utah.
292	[(mm)] (pp) "Ultimate user" means any person who lawfully possesses a controlled
293	substance for his own use, for the use of a member of his household, or for administration to an
294	animal owned by him or a member of his household.
295	(2) If a term used in this chapter is not defined, the definition and terms of Title 76,
296	Utah Criminal Code, shall apply.
297	Section 3. Section <b>58-37-4</b> is amended to read:
298	58-37-4. Schedules of controlled substances Schedules I through V Findings
299	required Specific substances included in schedules.
300	(1) There are established five schedules of controlled substances known as Schedules I,
301	II, III, IV, and V which shall consist of substances listed in this section.
302	(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
303	the official name, common or usual name, chemical name, or brand name designated:
304	(a) Schedule I:
305	(i) Unless specifically excepted or unless listed in another schedule, any of the
306	following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
307	ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
308	chemical designation:

310	(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
311	(B) Acetylmethadol;
312	(C) Allylprodine;
313	(D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
314	levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
315	(E) Alphameprodine;
316	(F) Alphamethadol;
317	(G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
318	propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
319	(H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
320	piperidinyl]-N-phenylpropanamide);
321	(I) Benzethidine;
322	(J) Betacetylmethadol;
323	(K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
324	piperidinyl]-N-phenylpropanamide);
325	(L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
326	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
327	(M) Betameprodine;
328	(N) Betamethadol;
329	(O) Betaprodine;
330	(P) Clonitazene;
331	(Q) Dextromoramide;
332	(R) Diampromide;
333	(S) Diethylthiambutene;
334	(T) Difenoxin;
335	(U) Dimenoxadol;
336	(V) Dimepheptanol;
337	(W) Dimethylthiambutene:

```
338
             (X) Dioxaphetyl butyrate;
339
             (Y) Dipipanone;
340
             (Z) Ethylmethylthiambutene;
341
             (AA) Etonitazene;
342
             (BB) Etoxeridine;
343
             (CC) Furethidine;
344
             (DD) Hydroxypethidine;
345
             (EE) Ketobemidone;
346
             (FF) Levomoramide;
347
             (GG) Levophenacylmorphan;
348
             (HH) Morpheridine;
349
             (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
350
             (JJ) Noracymethadol;
351
             (KK) Norlevorphanol;
352
             (LL) Normethadone;
353
             (MM) Norpipanone;
             (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]
354
355
      propanamide;
356
             (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
357
             (PP) Phenadoxone;
358
             (QQ) Phenampromide;
359
             (RR) Phenomorphan;
360
             (SS) Phenoperidine;
361
             (TT) Piritramide;
362
             (UU) Proheptazine;
363
             (VV) Properidine;
364
             (WW) Propiram;
365
             (XX) Racemoramide;
```

366	(YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
367	(ZZ) Tilidine;
368	(AAA) Trimeperidine;
369	(BBB) 3-methylfentanyl, including the optical and geometric isomers
370	(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
371	(CCC) 3-methylthiofentanyl
372	(N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
373	(ii) Unless specifically excepted or unless listed in another schedule, any of the
374	following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
375	salts, isomers, and salts of isomers is possible within the specific chemical designation:
376	(A) Acetorphine;
377	(B) Acetyldihydrocodeine;
378	(C) Benzylmorphine;
379	(D) Codeine methylbromide;
380	(E) Codeine-N-Oxide;
381	(F) Cyprenorphine;
382	(G) Desomorphine;
383	(H) Dihydromorphine;
384	(I) Drotebanol;
385	(J) Etorphine (except hydrochloride salt);
386	(K) Heroin;
387	(L) Hydromorphinol;
388	(M) Methyldesorphine;
389	(N) Methylhydromorphine;
390	(O) Morphine methylbromide;
391	(P) Morphine methylsulfonate;
392	(Q) Morphine-N-Oxide;
393	(R) Myrophine;

394	(S) Nicocodeine;
395	(T) Nicomorphine;
396	(U) Normorphine;
397	(V) Pholcodine; and
398	(W) Thebacon.
399	(iii) Unless specifically excepted or unless listed in another schedule, any material,
400	compound, mixture, or preparation which contains any quantity of the following hallucinogenic
401	substances, or which contains any of their salts, isomers, and salts of isomers when the
402	existence of the salts, isomers, and salts of isomers is possible within the specific chemical
403	designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
404	geometric isomers:
405	(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
406	$\alpha$ -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; $\alpha$ -ET; and AET;
407	(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
408	4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
409	(C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
410	2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
411	(D) 2,5-dimethoxyamphetamine, some trade or other names:
412	2,5-dimethoxy-α-methylphenethylamine; 2,5-DMA;
413	(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
414	(F) 4-methoxyamphetamine, some trade or other names:
415	4-methoxy-α-methylphenethylamine; paramethoxyamphetamine, PMA;
416	(G) 5-methoxy-3,4-methylenedioxyamphetamine;
417	(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
418	4-methyl-2,5-dimethoxy-α-methylphenethylamine; "DOM"; and "STP";
419	(I) 3,4-methylenedioxy amphetamine;
120	(J) 3,4-methylenedioxymethamphetamine (MDMA);
421	(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-

422	alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
423	(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
424	N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
425	(M) 3,4,5-trimethoxy amphetamine;
426	(N) Bufotenine, some trade and other names:
427	$3\hbox{-}(\beta\hbox{-Dimethylaminoethyl})\hbox{-}5\hbox{-hydroxyindole};\ 3\hbox{-}(2\hbox{-dimethylaminoethyl})\hbox{-}5\hbox{-indolol};\ N,$
428	N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
429	(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
430	(P) Dimethyltryptamine, some trade or other names: DMT;
431	(Q) Ibogaine, some trade and other names:
432	7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
433	[5,4-b] indole; Tabernanthe iboga;
434	(R) Lysergic acid diethylamide;
435	(S) Marijuana;
436	(T) Mescaline;
437	(U) Parahexyl, some trade or other names:
438	3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
439	(V) Peyote, meaning all parts of the plant presently classified botanically as
440	Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
441	any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
442	preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
443	(W) N-ethyl-3-piperidyl benzilate;
444	(X) N-methyl-3-piperidyl benzilate;
445	(Y) Psilocybin;
446	(Z) Psilocyn;
447	(AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the
448	plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
449	and their isomers with similar chemical structure and pharmacological activity such as the

450	following: $\Delta 1$ cis or trans tetrahydrocannabinol, and their optical isomers $\Delta 6$ cis or trans
451	tetrahydrocannabinol, and their optical isomers $\Delta 3,4$ cis or trans tetrahydrocannabinol, and its
452	optical isomers, and since nomenclature of these substances is not internationally standardized,
453	compounds of these structures, regardless of numerical designation of atomic positions
454	covered;
455	(BB) Ethylamine analog of phencyclidine, some trade or other names:
456	N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
457	N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
458	(CC) Pyrrolidine analog of phencyclidine, some trade or other names:
459	1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
460	(DD) Thiophene analog of phencyclidine, some trade or other names:
461	1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
462	(EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
463	(iv) Unless specifically excepted or unless listed in another schedule, any material
464	compound, mixture, or preparation which contains any quantity of the following substances
465	having a depressant effect on the central nervous system, including its salts, isomers, and salts
466	of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
467	specific chemical designation:
468	(A) Mecloqualone; and
469	(B) Methaqualone.
470	(v) Any material, compound, mixture, or preparation containing any quantity of the
471	following substances having a stimulant effect on the central nervous system, including their
472	salts, isomers, and salts of isomers:
473	(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
474	4,5-dihydro-5-phenyl-2-oxazolamine;
475	(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
476	alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
477	(C) Fenethylline;

478	(D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
479	alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
480	alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
481	methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
482	optical isomers;
483	(E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
484	(F) N-ethylamphetamine; and
485	(G) N,N-dimethylamphetamine, also known as
486	N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
487	(vi) Any material, compound, mixture, or preparation which contains any quantity of
488	the following substances, including their optical isomers, salts, and salts of isomers, subject to
489	temporary emergency scheduling:
490	(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
491	(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
492	(vii) Unless specifically excepted or unless listed in another schedule, any material,
493	compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
494	(gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
495	(b) Schedule II:
496	(i) Unless specifically excepted or unless listed in another schedule, any of the
497	following substances whether produced directly or indirectly by extraction from substances of
498	vegetable origin, or independently by means of chemical synthesis, or by a combination of
499	extraction and chemical synthesis:
500	(A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
501	opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,
502	and their respective salts, but including:
503	(I) Raw opium;
504	(II) Opium extracts;
505	(III) Onium fluid:

506	(IV) Powdered opium;
507	(V) Granulated opium;
508	(VI) Tincture of opium;
509	(VII) Codeine;
510	(VIII) Ethylmorphine;
511	(IX) Etorphine hydrochloride;
512	(X) Hydrocodone;
513	(XI) Hydromorphone;
514	(XII) Metopon;
515	(XIII) Morphine;
516	(XIV) Oxycodone;
517	(XV) Oxymorphone; and
518	(XVI) Thebaine;
519	(B) Any salt, compound, derivative, or preparation which is chemically equivalent or
520	identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
521	substances may not include the isoquinoline alkaloids of opium;
522	(C) Opium poppy and poppy straw;
523	(D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
524	any salt, compound, derivative, or preparation which is chemically equivalent or identical with
525	any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
526	and salts of isomers and derivatives, whether derived from the coca plant or synthetically
527	produced, except the substances may not include decocainized coca leaves or extraction of coca
528	leaves, which extractions do not contain cocaine or ecgonine; and
529	(E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
530	liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
531	(ii) Unless specifically excepted or unless listed in another schedule, any of the
532	following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
533	ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific

534	chemical designation, except dextrorphan and levopropoxyphene:
535	(A) Alfentanil;
536	(B) Alphaprodine;
537	(C) Anileridine;
538	(D) Bezitramide;
539	(E) Bulk dextropropoxyphene (nondosage forms);
540	(F) Carfentanil;
541	(G) Dihydrocodeine;
542	(H) Diphenoxylate;
543	(I) Fentanyl;
544	(J) Isomethadone;
545	(K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
546	levomethadyl acetate, or LAAM;
547	(L) Levomethorphan;
548	(M) Levorphanol;
549	(N) Metazocine;
550	(O) Methadone;
551	(P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
552	(Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
553	acid;
554	(R) Pethidine (meperidine);
555	(S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
556	(T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
557	(U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
558	(V) Phenazocine;
559	(W) Piminodine;
560	(X) Racemethorphan;
561	(Y) Racemorphan;

562	(Z) Remifentanil; and
563	(AA) Sufentanil.
564	(iii) Unless specifically excepted or unless listed in another schedule, any material,
565	compound, mixture, or preparation which contains any quantity of the following substances
566	having a stimulant effect on the central nervous system:
567	(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
568	(B) Methamphetamine, its salts, isomers, and salts of its isomers;
569	(C) Phenmetrazine and its salts; and
570	(D) Methylphenidate.
571	(iv) Unless specifically excepted or unless listed in another schedule, any material,
572	compound, mixture, or preparation which contains any quantity of the following substances
573	having a depressant effect on the central nervous system, including its salts, isomers, and salts
574	of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
575	specific chemical designation:
576	(A) Amobarbital;
577	(B) Glutethimide;
578	(C) Pentobarbital;
579	(D) Phencyclidine;
580	(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
581	1-piperidinocyclohexanecarbonitrile (PCC); and
582	(F) Secobarbital.
583	(v) Unless specifically excepted or unless listed in another schedule, any material,
584	compound, mixture, or preparation which contains any quantity of Phenylacetone.
585	Some of these substances may be known by trade or other names: phenyl-2-propanone,
586	P2P; benzyl methyl ketone, methyl benzyl ketone.
587	(vi) Nabilone, another name for nabilone:
588	(±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,

6-dimethyl-9H-dibenzo[b,d]pyran-9-one.

590	(a)	Schedule	TIT.
.190	I C	i Schedule	

- (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- (A) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitive composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;
- 602 (B) Benzphetamine;
  - (C) Chlorphentermine;
    - (D) Clortermine; and
- 605 (E) Phendimetrazine.
  - (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
  - (A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which are not listed in any schedule;
  - (B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug Administration for marketing only as a suppository;
  - (C) Any substance which contains any quantity of a derivative of barbituric acid or any salt of any of them;
  - (D) Chlorhexadol;

618	(E) Buprenorphine;
619	(F) Any drug product containing gamma hydroxybutyric acid, including its salts,
620	isomers, and salts of isomers, for which an application is approved under the federal Food,
621	Drug, and Cosmetic Act, Section 505;
622	(G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
623	± -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone[:];
624	(H) Lysergic acid;
625	(I) Lysergic acid amide;
626	(J) Methyprylon;
627	(K) Sulfondiethylmethane;
628	(L) Sulfonethylmethane;
629	(M) Sulfonmethane; and
630	(N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
631	tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
632	2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
633	4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
634	flupyrazapon.
635	(iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
636	U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
637	(6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
638	(-)-delta-9-(trans)-tetrahydrocannabinol.
639	(iv) Nalorphine.
640	(v) Unless specifically excepted or unless listed in another schedule, any material,
641	compound, mixture, or preparation containing limited quantities of any of the following
642	narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
643	(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
644	milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
645	opium;

646 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 647 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized 648 therapeutic amounts; 649 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more 650 than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline 651 alkaloid of opium; 652 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more 653 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in 654 recognized therapeutic amounts; 655 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 656 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized 657 therapeutic amounts; 658 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more 659 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in 660 recognized therapeutic amounts; 661 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not 662 more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in 663 recognized therapeutic amounts; and 664 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts. 665 666 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids 667 including any of the following or any isomer, ester, salt, or derivative of the following that 668 promotes muscle growth: 669 (A) Boldenone; 670 (B) Chlorotestosterone (4-chlortestosterone); 671 (C) Clostebol;

(D) Dehydrochlormethyltestosterone;

(E) Dihydrotestosterone (4-dihydrotestosterone);

672

674	(F) Drostanolone;
675	(G) Ethylestrenol;
676	(H) Fluoxymesterone;
677	(I) Formebulone (formebolone);
678	(J) Mesterolone;
679	(K) Methandienone;
680	(L) Methandranone;
681	(M) Methandriol;
682	(N) Methandrostenolone;
683	(O) Methenolone;
684	(P) Methyltestosterone;
685	(Q) Mibolerone;
686	(R) Nandrolone;
687	(S) Norethandrolone;
688	(T) Oxandrolone;
689	(U) Oxymesterone;
690	(V) Oxymetholone;
691	(W) Stanolone;
692	(X) Stanozolol;
693	(Y) Testolactone;
694	(Z) Testosterone; and
695	(AA) Trenbolone.
696	Anabolic steroids expressly intended for administration through implants to cattle or
697	other nonhuman species, and approved by the Secretary of Health and Human Services for use,
698	may not be classified as a controlled substance.
699	(d) Schedule IV:
700	(i) Unless specifically excepted or unless listed in another schedule, any material,
701	compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not

702 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them. 703 (ii) Unless specifically excepted or unless listed in another schedule, any material, 704 compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and 705 706 salts of isomers is possible within the specific chemical designation: 707 (A) Alprazolam; 708 (B) Barbital; 709 (C) Bromazepam; 710 (D) Butorphanol; 711 (E) Camazepam; 712 (F) Chloral betaine; 713 (G) Chloral hydrate; 714 (H) Chlordiazepoxide; 715 (I) Clobazam; 716 (J) Clonazepam; 717 (K) Clorazepate; 718 (L) Clotiazepam; 719 (M) Cloxazolam; 720 (N) Delorazepam; 721 (O) Diazepam; 722 (P) Dichloralphenazone; 723 (Q) Estazolam; 724 (R) Ethchlorvynol; 725 (S) Ethinamate; 726 (T) Ethyl loflazepate; 727 (U) Fludiazepam; 728 (V) Flunitrazepam;

729

(W) Flurazepam;

730	(X) Halazepam;
731	(Y) Haloxazolam;
732	(Z) Ketazolam;
733	(AA) Loprazolam;
734	(BB) Lorazepam;
735	(CC) Lormetazepam;
736	(DD) Mebutamate;
737	(EE) Medazepam;
738	(FF) Meprobamate;
739	(GG) Methohexital;
740	(HH) Methylphenobarbital (mephobarbital):
741	(II) Midazolam;
742	(JJ) Nimetazepam;
743	(KK) Nitrazepam;
744	(LL) Nordiazepam;
745	(MM) Oxazepam;
746	(NN) Oxazolam;
747	(OO) Paraldehyde;
748	(PP) Pentazocine;
749	(QQ) Petrichloral;
750	(RR) Phenobarbital;
751	(SS) Pinazepam;
752	(TT) Prazepam;
753	(UU) Quazepam;
754	(VV) Temazepam;
755	(WW) Tetrazepam;
756	(XX) Triazolam;

(YY) Zaleplon; and

758 (ZZ) Zolpidem.

763

764

765

766

- 759 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains 760 any quantity of the following substances, including its salts, isomers whether optical, position, 761 or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of 762 isomers is possible.
  - (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 768 (A) Cathine ((+)-norpseudoephedrine);
- 769 (B) Diethylpropion;
- 770 (C) Fencamfamine;
- 771 (D) Fenproprex;
- 772 (E) Mazindol;
- 773 (F) Mefenorex;
- 774 (G) Modafinil;
- 775 (H) Pemoline, including organometallic complexes and chelates thereof;
- 776 (I) Phentermine;
- 777 (J) Pipradrol;
- 778 (K) Sibutramine; and
- 779 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
- 780 (v) Unless specifically excepted or unless listed in another schedule, any material,
  781 compound, mixture, or preparation which contains any quantity of dextropropoxyphene
  782 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
- (e) Schedule V: Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in

786 sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal 787 qualities other than those possessed by the narcotic drug alone: 788 (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams; 789 (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 790 grams; 791 (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 792 grams; 793 (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of 794 atropine sulfate per dosage unit; 795 (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; 796 (vi) not more than 0.5 milligram of different and not less than 25 micrograms of 797 atropine sulfate per dosage unit; and 798 (vii) unless specifically exempted or excluded or unless listed in another schedule, any 799 material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant 800 effect on the central nervous system, including its salts, isomers, and salts of isomers. 801 Section 4. Section **58-37-8** is amended to read: 802 58-37-8. Prohibited acts -- Penalties. 803 (1) Prohibited acts A -- Penalties: 804 (a) Except as authorized by this chapter, it is unlawful for any person to knowingly and 805 intentionally: 806 (i) produce, manufacture, or dispense, or to possess with intent to produce, 807 manufacture, or dispense, a controlled or counterfeit substance; 808 (ii) distribute a controlled or counterfeit substance, or to agree, consent, offer, or 809 arrange to distribute a controlled or counterfeit substance;

- (iii) possess a controlled or counterfeit substance with intent to distribute; or
- 811 (iv) engage in a continuing criminal enterprise where:

810

812 (A) the person participates, directs, or engages in conduct which results in any 813 violation of any provision of Title 58, Chapters 37, 37a, 37b, 37c, or 37d that is a felony; and

(B) the violation is a part of a continuing series of two or more violations of Title 58, Chapters 37, 37a, 37b, 37c, or 37d on separate occasions that are undertaken in concert with five or more persons with respect to whom the person occupies a position of organizer, supervisor, or any other position of management.

- (b) Any person convicted of violating Subsection (1)(a) with respect to:
- (i) a substance classified in Schedule I or II, a controlled substance analog, or gammahydroxybutyric acid as listed in Schedule III is guilty of a second degree felony and upon a second or subsequent conviction is guilty of a first degree felony;
- (ii) a substance classified in Schedule III or IV, or marijuana, is guilty of a third degree felony, and upon a second or subsequent conviction is guilty of a second degree felony; or
- (iii) a substance classified in Schedule V is guilty of a class A misdemeanor and upon a second or subsequent conviction is guilty of a third degree felony.
- (c) Any person who has been convicted of a violation of Subsection (1)(a)(ii) or (iii) may be sentenced to imprisonment for an indeterminate term as provided by law, but if the trier of fact finds a firearm as defined in Section 76-10-501 was used, carried, or possessed on his person or in his immediate possession during the commission or in furtherance of the offense, the court shall additionally sentence the person convicted for a term of one year to run consecutively and not concurrently; and the court may additionally sentence the person convicted for an indeterminate term not to exceed five years to run consecutively and not concurrently.
- (d) Any person convicted of violating Subsection (1)(a)(iv) is guilty of a first degree felony punishable by imprisonment for an indeterminate term of not less than seven years and which may be for life. Imposition or execution of the sentence may not be suspended, and the person is not eligible for probation.
  - (2) Prohibited acts B -- Penalties:
  - (a) It is unlawful:

(i) for any person knowingly and intentionally to possess or use a controlled substance analog or a controlled substance, unless it was obtained under a valid prescription or order,

directly from a practitioner while acting in the course of his professional practice, or as otherwise authorized by this chapter;

- (ii) for any owner, tenant, licensee, or person in control of any building, room, tenement, vehicle, boat, aircraft, or other place knowingly and intentionally to permit them to be occupied by persons unlawfully possessing, using, or distributing controlled substances in any of those locations; or
- (iii) for any person knowingly and intentionally to possess an altered or forged prescription or written order for a controlled substance.
  - (b) Any person convicted of violating Subsection (2)(a)(i) with respect to:
  - (i) marijuana, if the amount is 100 pounds or more, is guilty of a second degree felony;
- (ii) a substance classified in Schedule I or II, marijuana, if the amount is more than 16 ounces, but less than 100 pounds, or a controlled substance analog, is guilty of a third degree felony; or
- (iii) marijuana, if the marijuana is not in the form of an extracted resin from any part of the plant, and the amount is more than one ounce but less than 16 ounces, is guilty of a class A misdemeanor.
- (c) Upon a person's conviction of a violation of this Subsection (2) subsequent to a conviction under Subsection (1)(a), that person shall be sentenced to a one degree greater penalty than provided in this Subsection (2).
- (d) Any person who violates Subsection (2)(a)(i) with respect to all other controlled substances not included in Subsection (2)(b)(i), (ii), or (iii), including less than one ounce of marijuana, is guilty of a class B misdemeanor. Upon a second conviction the person is guilty of a class A misdemeanor, and upon a third or subsequent conviction the person is guilty of a third degree felony.
- (e) Any person convicted of violating Subsection (2)(a)(i) while inside the exterior boundaries of property occupied by any correctional facility as defined in Section 64-13-1 or any public jail or other place of confinement shall be sentenced to a penalty one degree greater than provided in Subsection (2)(b), and if the conviction is with respect to controlled

870	substances as listed in:
871	(i) Subsection (2)(b), the person may be sentenced to imprisonment for an
872	indeterminate term as provided by law, and:
873	(A) the court shall additionally sentence the person convicted to a term of one year to
874	run consecutively and not concurrently; and
875	(B) the court may additionally sentence the person convicted for an indeterminate term
876	not to exceed five years to run consecutively and not concurrently; and
877	(ii) Subsection (2)(d), the person may be sentenced to imprisonment for an
878	indeterminate term as provided by law, and the court shall additionally sentence the person
879	convicted to a term of six months to run consecutively and not concurrently.
880	(f) Any person convicted of violating Subsection (2)(a)(ii) or (2)(a)(iii) is:
881	(i) on a first conviction, guilty of a class B misdemeanor;
882	(ii) on a second conviction, guilty of a class A misdemeanor; and
883	(iii) on a third or subsequent conviction, guilty of a third degree felony.
884	(g) A person is subject to the penalties under Subsection (4)(c) who, in an offense not
885	amounting to a violation of Section 76-5-207:
886	(i) violates Subsection (2)(a)(i) by knowingly and intentionally having in his body any
887	measurable amount of a controlled substance; and
888	(ii) operates a motor vehicle as defined in Section 76-5-207 in a negligent manner,
889	causing serious bodily injury as defined in Section 76-1-601 or the death of another.

(3) Prohibited acts C -- Penalties:

890

891

892

893

894

895

896

- (a) It is unlawful for any person knowingly and intentionally:
- (i) to use in the course of the manufacture or distribution of a controlled substance a license number which is fictitious, revoked, suspended, or issued to another person or, for the purpose of obtaining a controlled substance, to assume the title of, or represent himself to be, a manufacturer, wholesaler, apothecary, physician, dentist, veterinarian, or other authorized person;
  - (ii) to acquire or obtain possession of, to procure or attempt to procure the

administration of, to obtain a prescription for, to prescribe or dispense to any person known to be attempting to acquire or obtain possession of, or to procure the administration of any controlled substance by misrepresentation or failure by the person to disclose his receiving any controlled substance from another source, fraud, forgery, deception, subterfuge, alteration of a prescription or written order for a controlled substance, or the use of a false name or address;

- (iii) to make any false or forged prescription or written order for a controlled substance, or to utter the same, or to alter any prescription or written order issued or written under the terms of this chapter; or
- (iv) to make, distribute, or possess any punch, die, plate, stone, or other thing designed to print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of another or any likeness of any of the foregoing upon any drug or container or labeling so as to render any drug a counterfeit controlled substance.
- (b) Any person convicted of violating Subsection (3)(a) is guilty of a third degree felony.
  - (4) Prohibited acts D -- Penalties:

- (a) Notwithstanding other provisions of this section, a person not authorized under this chapter who commits any act declared to be unlawful under this section, Title 58, Chapter 37a, Utah Drug Paraphernalia Act, or under Title 58, Chapter 37b, Imitation Controlled Substances Act, is upon conviction subject to the penalties and classifications under this Subsection (4) if the trier of fact finds the act is committed:
- (i) in a public or private elementary or secondary school or on the grounds of any of those schools;
- (ii) in a public or private vocational school or postsecondary institution or on the grounds of any of those schools or institutions;
- (iii) in those portions of any building, park, stadium, or other structure or grounds which are, at the time of the act, being used for an activity sponsored by or through a school or institution under Subsections (4)(a)(i) and (ii);
  - (iv) in or on the grounds of a preschool or child-care facility;

926	(v) in a public park, amusement park, arcade, or recreation center;
927	(vi) in or on the grounds of a house of worship as defined in Section 76-10-501;
928	(vii) in a shopping mall, sports facility, stadium, arena, theater, movie house,
929	playhouse, or parking lot or structure adjacent thereto;
930	(viii) in a public parking lot or structure;
931	(ix) within 1,000 feet of any structure, facility, or grounds included in Subsections
932	(4)(a)(i) through (viii);
933	(x) in the immediate presence of a person younger than 18 years of age, regardless of
934	where the act occurs; or
935	(xi) for the purpose of facilitating, arranging, or causing the transport, delivery, or
936	distribution of a substance in violation of this section to an inmate or on the grounds of any
937	correctional facility as defined in Section 76-8-311.3.
938	(b) A person convicted under this Subsection (4) is guilty of a first degree felony and
939	shall be imprisoned for a term of not less than five years if the penalty that would otherwise
940	have been established but for this subsection would have been a first degree felony. Imposition
941	or execution of the sentence may not be suspended, and the person is not eligible for probation.
942	(c) If the classification that would otherwise have been established would have been
943	less than a first degree felony but for this Subsection (4), a person convicted under Subsection
944	(2)(g) or this Subsection (4) is guilty of one degree more than the maximum penalty prescribed
945	for that offense.
946	(d) (i) If the violation is of Subsection (4)(a)(xi):
947	(A) the person may be sentenced to imprisonment for an indeterminate term as
948	provided by law, and the court shall additionally sentence the person convicted for a term of
949	one year to run consecutively and not concurrently; and
950	(B) the court may additionally sentence the person convicted for an indeterminate term
951	not to exceed five years to run consecutively and not concurrently; and

(ii) the penalties under this Subsection (4)(d) apply also to any person who, acting with

the mental state required for the commission of an offense, directly or indirectly solicits,

952

requests, commands, coerces, encourages, or intentionally aids another person to commit a violation of Subsection (4)(a)(xi).

- (e) It is not a defense to a prosecution under this Subsection (4) that the actor mistakenly believed the individual to be 18 years of age or older at the time of the offense or was unaware of the individual's true age; nor that the actor mistakenly believed that the location where the act occurred was not as described in Subsection (4)(a) or was unaware that the location where the act occurred was as described in Subsection (4)(a).
- (5) Any violation of this chapter for which no penalty is specified is a class B misdemeanor.
- (6) (a) Any penalty imposed for violation of this section is in addition to, and not in lieu of, any civil or administrative penalty or sanction authorized by law.
- (b) Where violation of this chapter violates a federal law or the law of another state, conviction or acquittal under federal law or the law of another state for the same act is a bar to prosecution in this state.
- (7) In any prosecution for a violation of this chapter, evidence or proof which shows a person or persons produced, manufactured, possessed, distributed, or dispensed a controlled substance or substances, is prima facie evidence that the person or persons did so with knowledge of the character of the substance or substances.
- (8) This section does not prohibit a veterinarian, in good faith and in the course of his professional practice only and not for humans, from prescribing, dispensing, or administering controlled substances or from causing the substances to be administered by an assistant or orderly under his direction and supervision.
  - (9) Civil or criminal liability may not be imposed under this section on:
- (a) any person registered under [the Controlled Substances Act] this chapter who manufactures, distributes, or possesses an imitation controlled substance for use as a placebo or investigational new drug by a registered practitioner in the ordinary course of professional practice or research; or
  - (b) any law enforcement officer acting in the course and legitimate scope of his

H.B. 60 Enrolled Copy employment.

- (10) (a) Civil or criminal liability may not be imposed under this section on any Indian, as defined in Subsection 58-37-2(1)(v), who uses, possesses, or transports peyote for bona fide traditional ceremonial purposes in connection with the practice of a traditional Indian religion as defined in Subsection 58-37-2(1)(w).
- (b) In a prosecution alleging violation of this section regarding peyote as defined in Subsection 58-37-4(2)(a)(iii)(V), it is an affirmative defense that the peyote was used, possessed, or transported by an Indian for bona fide traditional ceremonial purposes in connection with the practice of a traditional Indian religion.
- (c) (i) The defendant shall provide written notice of intent to claim an affirmative defense under this Subsection (10) as soon as practicable, but not later than ten days prior to trial.
  - (ii) The notice shall include the specific claims of the affirmative defense.
- (iii) The court may waive the notice requirement in the interest of justice for good cause shown, if the prosecutor is not unfairly prejudiced by the lack of timely notice.
- (d) The defendant shall establish the affirmative defense under this Subsection (10) by a preponderance of the evidence. If the defense is established, it is a complete defense to the charges.
- [(10)] (11) If any provision of this chapter, or the application of any provision to any person or circumstances, is held invalid, the remainder of this chapter shall be given effect without the invalid provision or application.